<DOC>
	<DOCNO>NCT00019669</DOCNO>
	<brief_summary>RATIONALE : Vaccines may make body build immune response kill tumor cell . It yet know whether combine melanoma vaccine interleukin-2 effective vaccine therapy alone treat metastatic melanoma . PURPOSE : Phase II trial compare effectiveness melanoma vaccine interleukin-2 melanoma vaccine alone treat patient metastatic melanoma respond previous treatment .</brief_summary>
	<brief_title>Vaccine Therapy With Without Interleukin-2 Treating Patients With Metastatic Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare clinical response patient metastatic melanoma treat immunization recombinant fowlpox vaccine administer either intravenously intramuscularly , without interleukin-2 ( IL-2 ) . - Compare immune response patient treatment regimen . - Compare toxicity profile regimens patient . OUTLINE : This partially randomize study . Patients randomize 1 3 treatment cohort . - Cohort 1 : Patients receive recombinant fowlpox virus encode gp100 peptide ( fowlpox vaccine ) IV every 4 week 4 dos . ( Closed accrual 6/21/02 . ) - Cohort 2 : Patients receive fowlpox vaccine intramuscularly ( IM ) every 4 week 4 dos . ( Closed accrual 6/21/04 . ) - Cohort 3 ( patient need immediate interleukin-2 [ IL-2 ] disease progression treatment cohorts 1 2 ) : Patients receive fowlpox vaccine either IV IM* every 4 week 4 dos IL-2 IV every 8 hour maximum 12 dos begin 24 hour fowlpox vaccine . NOTE : *The IM route administration select preferred route administration cohorts 1 2 - Expanded cohort 2 ( open accrual 7/19/02 ) : Patients receive fowlpox vaccine IM every 4 week 4 dos . Upon disease progression , patient receive fowlpox vaccine IL-2 IV every 8 hour maximum 12 dos begin 24 hour fowlpox vaccine . ( Closed accrual 12/4/03 . ) In cohort , 3-4 week last injection , patient achieve complete remission may receive maximum additional 2 course therapy . Patients respond disease may receive repeat vaccination 8 course . Patients response progressive disease cohort receive IL-2 may treat fowlpox vaccine IL-2 cohort 3 . Patients randomized receive IL-2 may receive additional IL-2 therapy . PROJECTED ACCRUAL : A maximum 84 patient ( 24 cohort 1 2 , 19-33 cohort 3 , 27 expand cohort 2 ) accrue study within 1 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven metastatic melanoma fail standard treatment Measurable disease HLAA201 positive PATIENT CHARACTERISTICS : Age : 16 Performance status : ECOG 02 Life expectancy : More 3 month Hematopoietic : WBC ≥ 3,000/mm^3 Platelet count ≥ 90,000/mm^3 No coagulation disorder Hepatic : Bilirubin ≤ 1.6 mg/dL ( le 3.0 mg/dL patient Gilbert 's syndrome ) AST/ALT &lt; 2 time normal Hepatitis B surface antigen negative Renal : Creatinine ≤ 2.0 mg/dL Cardiovascular : No major cardiovascular disease No cardiac ischemia stress thallium test comparable test* No myocardial infarction* No cardiac arrhythmias* NOTE : *In order eligible receive interleukin2 ( IL2 ) Pulmonary : No major respiratory disease No obstructive restrictive pulmonary disease* NOTE : *In order eligible receive IL2 Immunologic : No autoimmune disease No known immunodeficiency disease No primary secondary immunodeficiency No allergy egg No active systemic infection HIV negative Other : Not pregnant Negative pregnancy test Fertile patient must use effective contraception No active major medical illness* NOTE : *In order eligible receive IL2 PRIOR CONCURRENT THERAPY : Biologic therapy : No prior gp100 vaccination Chemotherapy : Not specify Endocrine therapy : No concurrent steroids Radiotherapy : Not specify Surgery : Prior surgery malignancy allow Other : At least 3 week since prior therapy malignancy</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2004</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>